10,434 Shares in Prothena Co. plc (NASDAQ:PRTA) Acquired by Teacher Retirement System of Texas

Teacher Retirement System of Texas bought a new stake in Prothena Co. plc ( NASDAQ:PRTA – Free Report ) in the 4th quarter, Holdings Channel.com reports.

The fund bought 10,434 shares of the biotechnology company’s stock, valued at approximately $145,000. Several other hedge funds also recently bought and sold shares of the company. Intech Investment Management LLC acquired a new stake in Prothena during the 3rd quarter worth $210,000.



The Manufacturers Life Insurance Company boosted its holdings in shares of Prothena by 3.8% in the third quarter. The Manufacturers Life Insurance Company now owns 86,071 shares of the biotechnology company’s stock valued at $1,440,000 after buying an additional 3,163 shares during the period.

BNP Paribas Financial Markets raised its holdings in shares of Prothena by 44.6% during the third quarter. BNP Paribas Financial Markets now owns 55,842 shares of the biotechnology company’s stock worth $934,000 after acquiring an additional 17,230 shares during the period.

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Prothena by 1,122.9% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 526,748 shares of the biotechnology company’s stock valued at $8,812,000 after purchasing an additional 483,673 shares in the last quarter.

Finally, Wellington Management Group LLP grew its holdings in shares of Prothena by 14.8% during the third quarter. Wellington Management Group LLP now owns 4,178,788 shares of the biotechnology company’s stock worth $69,911,000 after buying an additional 539,359 shares in the last quarter.

97.08% of the stock is currently owned by institutional investors and hedge funds. Prothena Stock Up 3.

4 % NASDAQ:PRTA opened at $12.14 on Thursday. Prothena Co.

plc has a 12-month low of $11.42 and a 12-month high of $25.42.

The firm has a market capitalization of $653.46 million, a price-to-earnings ratio of -5.28 and a beta of -0.

02. The stock’s 50 day moving average price is $14.20 and its two-hundred day moving average price is $15.

38. Analysts Set New Price Targets PRTA has been the topic of a number of research reports. HC Wainwright reissued a “buy” rating and issued a $48.

00 price objective on shares of Prothena in a research report on Friday, February 21st. Oppenheimer upped their target price on Prothena from $58.00 to $62.

00 and gave the stock an “outperform” rating in a report on Friday, February 7th. Cantor Fitzgerald restated an “overweight” rating on shares of Prothena in a research note on Friday, February 21st. Bank of America dropped their price objective on Prothena from $26.

00 to $22.00 and set a “neutral” rating on the stock in a research note on Thursday, December 19th. Finally, Royal Bank of Canada decreased their target price on shares of Prothena from $24.

00 to $20.00 and set a “sector perform” rating for the company in a research note on Friday, February 21st. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company.

According to data from MarketBeat.com, Prothena has an average rating of “Moderate Buy” and an average price target of $55.00.

Read Our Latest Report on Prothena Prothena Profile ( Free Report ) Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease. Featured Stories Want to see what other hedge funds are holding PRTA? Visit HoldingsChannel.

com to get the latest 13F filings and insider trades for Prothena Co. plc ( NASDAQ:PRTA – Free Report ). Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.

com's FREE daily email newsletter ..